Barclays PLC Candel Therapeutics, Inc. Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
A detailed history of Barclays PLC transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 28,688 shares of CADL stock, worth $199,668. This represents 0.0% of its overall portfolio holdings.
Number of Shares
28,688
Previous 28,688
-0.0%
Holding current value
$199,668
Previous $199,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CADL
# of Institutions
58Shares Held
6.45MCall Options Held
112KPut Options Held
130K-
Northpond Ventures, LLC1.94MShares$13.5 Million48.35% of portfolio
-
Vanguard Group Inc Valley Forge, PA946KShares$6.59 Million0.0% of portfolio
-
Black Rock Inc. New York, NY823KShares$5.73 Million0.0% of portfolio
-
State Street Corp Boston, MA492KShares$3.42 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA449KShares$3.13 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $201M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...